Ziprasidone

• Description:

  Ziprasidone (CP-88059), an orally active antipsychotic agent, is a combined 5-HT and dopamine receptor antagonist[1]. Ziprasidone mesylate trihydrate has affinities for Rat D2 (Ki=4.8 nM), 5-HT2A (Ki=0.42 nM) and 5-HT1A (Ki=3.4 nM) [1].

• Product Name Alternative:

  CP-88059

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  5-HT Receptor; Dopamine Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/ziprasidone.html

• Purity:

  99.35

• Solubility:

  DMSO : 13.33 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  ClC1=CC2=C(CC(N2)=O)C=C1CCN(CC3)CCN3C4=NSC5=C4C=CC=C5

• Molecular Formula:

  C21H21ClN4OS

• Molecular Weight:

  412.94

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Rollema H, et al. 5-HT (1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry. 2000;48 (3) :229-237.|[2]Zhi Su, et al. Block of hERG channel by ziprasidone: biophysical properties and molecular determinants. Biochem Pharmacol. 2006 Jan 12;71 (3) :278-86.|[3]Subin Park, et al. The effect of ziprasidone on body weight and energy expenditure in female rats. Metabolism. 2012 Jun;61 (6) :787-93.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  5-HT1 Receptor;5-HT2 Receptor; D2 Receptor; mLAG-3; α-1 microglobulin

• CAS Number:

  [146939-27-7]